Results 41 to 50 of about 16,167 (200)
Evidence for Aldosterone Antagonism in Heart Failure
Cardiac Failure ReviewActivation of the renin–angiotensin–aldosterone system is the ultimate pathophysiological hallmark in heart failure. Though aldosterone primarily appears to regulate electrolyte homeostasis by acting on distal nephrons in the kidneys, its effects are far-
Rishi Sethi +2 more
doaj +1 more source
Why are mineralocorticoid receptor antagonists cardioprotective? [PDF]
Naunyn-Schmiedeberg's Archives of Pharmacology, 2006 Two clinical trials, the Randomized ALdosterone Evaluation Study (RALES) and the EPlerenone HEart failure and SUrvival Study (EPHESUS), have recently shown that mineralocorticoid receptor (MR) antagonists reduce mortality in patients with heart failure on top of ACE inhibition.
Chai, W (Wenxia), Danser, Jan
openaire +3 more sources
Pharmacotherapy of resistant arterial hypertension [PDF]
Терапевтический архив, 2018 Pharmacotherapy of resistant arterial hypertension represents a serious problem, because today there are no clear algorithms of action in this clinical situation. The review discusses the key works in which the authors propose a solution to this problem.
N E Shepeleva, A V Rodionov, V V Fomin
doaj +3 more sources
Aldosterone Synthase Inhibitors for Cardiorenal Protection: Ready for Prime Time?
Kidney & Blood Pressure ResearchBackground: Aldosterone is the principal mineralocorticoid hormone and the final effector of the renin-angiotensin-aldosterone system. This hormone is primarily synthesized by the CYP11B2 enzyme and produced by the adrenal zona glomerulosa ...
Alessio Mazzieri +5 more
doaj +1 more source
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2020 Sodium‐glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure.
Milton Packer
doaj +1 more source
BMC Cardiovascular DisordersBackground Heart failure, particularly heart failure with reduced ejection fraction (HFrEF), represents a major global health challenge due to its high prevalence, rapid progression, and substantial mortality rates.
Xi-Wen Wang +9 more
doaj +1 more source
Hormone treatments in congestive heart failure
Journal of International Medical Research, 2018 The common ultimate pathological feature for all cardiovascular diseases, congestive heart failure (CHF), is now considered as one of the main public health burdens that is associated with grave implications. Neurohormonal systems play a critical role in
Lei Lei, Yuanjie Mao
doaj +1 more source
MINERALOCORTICOID ANTAGONISM: SELECTIVENESS GIVES MORE OPPORTUNITIES FOR HEART FAILURE MANAGEMENT
Российский кардиологический журнал, 2015 The review takes into consideration the novel data on heart failure treatment: application of mineralocorticoid antagonists. The pathogenetic points are highlighted that are proved by clinical trials, as epidemiological concerns. Further opportunites are
V. N. Soboleva, E. O. Taratukhin
doaj +1 more source
Mineralocorticoid receptor antagonists in dialysis patients [PDF]
Renal Replacement Therapy, 2016 Mineralocorticoid receptor (MR) antagonists are known to have beneficial effects in patients with cardiovascular disease without renal failure. However, there have been few published studies on the effectiveness of MR antagonists in dialysis patients, and most of the studies were small-sized.
Tawada, Mitsuhiro +4 more
openaire +1 more source
Journal of V. N. Karazin Kharkiv National University: Series Medicine, 2016 A comparative assessment of the effect of mineralocorticoid receptor antagonists on changes in galectin 3 and matrix metalloproteinase 1 fibrosis markers has been carried out on 106 examinations (average age (69 + 10.37) years) with type 2 DM and CCF of ...
T. A. Rudenko
doaj